Engineering focusing on cancer.
| Autor: | Keshari KR; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Imaging and Bioengineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: rahimikk@mskcc.org., Heller DA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Imaging and Bioengineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hellerd@mskcc.org., Boltyanskiy R; Center for Molecular Imaging and Bioengineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hricak H; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Imaging and Bioengineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Magaldi T; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Overholtzer M; Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Imaging and Bioengineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: overhom1@mskcc.org. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer cell [Cancer Cell] 2024 Jul 08; Vol. 42 (7), pp. 1138-1141. Date of Electronic Publication: 2024 Jun 06. |
| DOI: | 10.1016/j.ccell.2024.04.013 |
| Abstrakt: | While cancer research and care have benefited from revolutionary advances in the ability to manipulate and study living systems, the field is limited by a lack of synergy to leverage the power of engineering approaches. Cancer engineering is an emerging subfield of biomedical engineering that unifies engineering and cancer biology to better understand, diagnose, and treat cancer. We highlight cancer engineering's unique challenges, the importance of creating dedicated centers and departments that enable translational collaboration, and educational approaches to arm a new generation of scientists with engineering expertise and a fundamental understanding of cancer biology to transform clinical cancer care. Competing Interests: Declaration of interests K.R.K. is a founder with equity interest of Atish Technologies, Inc. and a member of the scientific advisory boards of NVision Imaging Technologies, Imaginostics, and Mi2. K.R.K. hold patents related to imaging and modulation of cellular metabolism. D.A.H. is a cofounder with equity interest of Lime Therapeutics Inc., Selectin Therapeutics Inc., and Nine Diagnostics, Inc.; an advisor with equity interest in Celine Therapeutics, Inc., Nanorobotics Inc., and Mediphage Bioceuticals Inc.; a member of the scientific advisory board of Concarlo Therapeutics Inc.; and an inventor of MSK intellectual property optioned to Metis Therapeutics. H.H. serves on the board of directors for iCAD and IBA. MSK and M.O. have financial interests in Elucida Oncology. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|